Breakthrough spinal injury drug shows promise

Dr. Adam Rogers, CEO of NervGen and a board-certified MD from Emory, joined" ChicagoLIVE" to discuss NVG-291, an experimental drug showing remarkable results in improving movement for patients with spinal cord injuries.